The addition of Vitrana strengthens Parexel’s ability to deliver an integrated PV solution that combines advanced AI and intelligent automation with safety services. Designed to be system-agnostic, Vitrana’s platform integrates seamlessly with existing safety databases, enabling clients to adopt flexible solutions that improve accuracy, accelerate timelines, and enhance compliance in an increasingly complex regulatory landscape.

With this acquisition, Parexel positions itself as a single partner offering both PV technology and services—responding to industry demand for more streamlined and unified operating models. Sanjay Vyas, President of Patient Safety Services & Clinical Logistics and Managing Director of India, said the integration will help manage growing regulatory volumes, simplify workflows, and allow experts to focus more on ensuring product and patient safety while delivering consistent operational efficiencies.

The integrated model is expected to deliver tangible benefits across the clinical trial lifecycle and post-approval stages, including improved pricing flexibility, faster issue resolution, and reduced complexity in vendor management. It also enhances site operations through better integration between electronic data capture and safety systems, along with more efficient handling of serious adverse events. Patients, in turn, may benefit from more accessible and user-friendly digital reporting channels.

Mohit Gupta, President and CEO of Vitrana, highlighted that joining Parexel will enable the company to scale its technology and expertise globally, further improving efficiency, quality, and compliance in pharmacovigilance.

Vitrana’s team and platform will be integrated into Parexel’s Patient Safety Services division, operating initially as “Vitrana – a Parexel Company.” The transition will be phased to ensure continuity for customers while aligning with product development and service delivery commitments.